anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The application discloses a liquid medicine for treating foot fungal infection, which is prepared from the following raw materials in parts by weight: 0.1-5 parts of radix sophorae flavescentis extract, 0.1-5 parts of fructus cnidii extract, 0.1-5 parts of wormwood extract, 0.1-5 parts of cortex dictamni extract, 5-10 parts of chlorhexidine acetate, 5-10 parts of polygonum cuspidatum extract, 5-15 parts of glycerol, 2-5 parts of peppermint oil and 1-40 parts of hydroxypropyl methyl cellulose. The invention contains the sophora flavescens extract which has the effects of clearing heat, drying dampness and sterilizing and has good relieving effect on skin itch. Fructus Cnidii extract has antiallergic effect. The cortex Dictamni Radicis has antiinflammatory, antiallergic and antibacterial effects. The giant knotweed rhizome extract and the chlorhexidine acetate are high-efficiency penetrating active substances, and can enhance the liquid medicine penetration so that the effect is deeper. The hydroxypropyl methyl cellulose and the glycerol realize the foot beautifying and moistening. The pharmaceutical composition is an external preparation, directly acts on pathogenic bacteria, and has the advantages of strong action effect, small toxic and side effects, mild dosage form and convenient use.
Fluticasone Furoate/Vilanterol ELLIPTA, like other drugs containing beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and also cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles [see Adverse Reactions (6.3)]. If such effects occur, Fluticasone Furoate/Vilanterol ELLIPTA may need to be discontinued. In addition, beta‑agonists have been reported to produce electrocardiographic changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression, although the clinical significance of these findings is unknown [see Clinical Pharmacology (12.2)]. Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.

In healthy subjects, large doses of inhaled fluticasone furoate/vilanterol (4 times the recommended dose of vilanterol, representing a 12- or 10-fold higher systemic exposure than seen in patients with COPD or asthma, respectively) have been associated with clinically significant prolongation of the QTc interval, which has the potential for producing ventricular arrhythmias. Therefore, Fluticasone Furoate/Vilanterol ELLIPTA, like other sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

In a mortality trial with a median treatment duration of 1.5 years in 16,568 patients with moderate COPD and cardiovascular disease, the annualized incidence rate of adjudicated cardiovascular events (composite of myocardial infarction, stroke, unstable angina, transient ischemic attack, or on-treatment death due to cardiovascular events) was 2.5 per 100 patient‑years for fluticasone furoate/vilanterol ELLIPTA 100/25 mcg, 2.7 for placebo, 2.4 for fluticasone furoate 100 mcg, and 2.6 for vilanterol 25 mcg. Adjudicated, on-treatment deaths due to cardiovascular events occurred in 82 patients receiving fluticasone furoate/vilanterol ELLIPTA 100/25 mcg, 86 patients receiving placebo, 80 patients receiving fluticasone furoate 100 mcg, and 90 patients receiving vilanterol 25 mcg (annualized incidence rate ranged from 1.2 to 1.3 per 100 patient-years for the treatment groups).
Persons who are using drugs that suppress the immune system, such as corticosteroids, including RYALTRIS, are more susceptible to infections than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids. In children or adults who have not had these diseases or been properly immunized, particular care should be taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affect the risk of developing a disseminated infection is not known. The safety and effectiveness of RYALTRIS have not been established in pediatric patients less than 12 years of age and RYALTRIS is not indicated for use in this population. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chickenpox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated (see the respective Prescribing Information for VZIG and IG). If chickenpox develops, treatment with antiviral agents may be considered.

Corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculous infections of the respiratory tract, untreated local or systemic fungal or bacterial infections, systemic viral or parasitic infections, or ocular herpes simplex because of the potential for worsening of these infections.
The Klein Laxative Tea is a pharmaceutical phytotherapeutic product that's been used for several years in Brazil for the treatment of constipation. This product contains fruit of Pimpinella anisum (green anises), fruit of Foeniculum vulgare (fennel), flowers of Sambucus nigra (elder tree) and flowers of Cassia angustifolia (senna). In spite of the beneficial effects of its components, separately demonstrated in vitro, it never had its effectiveness appraised in a randomized clinical trial.The purpose of this study was to evaluate the efficacy and safety of this product in a randomized crossover placebo-controlled clinical trial. Twenty patients presenting with the criteria of the American Association of Gastroenterology for chronic constipation were included, and concluded a two-phase crossover study. The primary endpoint was the evaluation of the intestinal transit time measured through radiological technique. The secondary endpoints were the number of evacuations, subjective impression of the quality in the intestinal habit, quality of life appraised through WHOQOL-brief and adverse effects.
The invention discloses an application of CD146 as a therapeutic target in preparation of a medicine for treating asthma airway remodeling. Application of CD146 as a therapeutic target in screening of drugs for treating asthma. The application of a substance inhibiting the expression of CD146 or a substance antagonizing CD146 in the preparation of a medicament for treating bronchial asthma; preferably in the preparation of medicaments for asthma airway remodeling. The invention discloses an application of detecting CD146 of a patient with bronchial asthma plasma, which finds expression difference of CD146 in serum of asthma and normal human for the first time, and the index can be used as a serum molecular marker of bronchial asthma. And the present study showed that HDM aggravates asthma airway remodeling by CD 146. Therefore, the CD146 can be used as a therapeutic target for screening and treating the application of the bronchial asthma. Antibodies against CD146 may also be used as a therapeutic strategy for bronchial asthma.
OBJECTIVES: The Healthy Recovery after Childbirth Clinic (HRCC) in Nova Scotia provides postpartum care to patients who experience obstetric anal sphincter injuries (OASIS). The purpose of this study was to describe characteristics associated with HRCC attendance, characteristics associated with a trial of labour in a subsequent delivery, and OASIS recurrence by HRCC attendance status.
METHODS: A retrospective cohort study using the Atlee Perinatal Database and clinical record review included primiparous individuals who sustained an OASIS at IWK Health in Halifax between 2013 and 2020. The χ2 and Fisher exact tests were performed to compare groups.
RESULTS: Of the 1041 individuals included, 67% attended HRCC. Attendance increased from 58% in 2013-2015 to 77% in 2019-2020. Younger age (<25 years) and smoking were associated with lower HRCC attendance (P = 0.07 and <0.01, respectively). Other characteristics, including area-level income and driving distance to HRCC, were not associated with attendance (P > 0.05). Of the 439 individuals who had a subsequent delivery, 92% had a trial of labour. Individuals with fourth-degree injury were less likely to attempt a trial of labour than those with third-degree injury (73% vs. 94%, P < 0.01). Of those who delivered vaginally, OASIS recurrence was similar in those who did and did not attend the HRCC (7.5% vs. 6.5%, P = 0.84).
CONCLUSIONS: HRCC attendance was high, but the disparity by age and smoking status suggests some barriers to access that should be explored. Although we found no difference in OASIS recurrence by HRCC attendance, more research with larger samples with adjustment for confounders is needed.
Patients receive gemtuzumab ozogamicin IV on days 1, 4, 7. Treatment continues for 35 days in the absence of disease progression or unacceptable toxicity. Responders and non-responders, without significant adverse events during the first course, may receive a second course of gemtuzumab ozogamicin within 60 days after course 1.
The UK OAGB/MGB collaborative group of 12 consultant bariatric surgeons was founded in 2017 and the data of 925 OAGB/MGB procedures were retrospectively collected and analysed in this cohort study. The treatment pathway is the SAME at each NHS centre. The indications for referral, consultations, and follow up after surgery are similar. This is agreed bariatric practice governed by British Obesity and Metabolic Surgery Society's \[BOMSS\] guidance.

The patients' age, BMI, presence of T2DM, comorbidities, Gastro-oesophageal reflux and hiatus hernia, Barrett's oesophagus, family history of upper gastro-intestinal cancer, and the patient choice were the main factors to influence the decision to the procedure type. Each centre is offering Roux en Y Gastric Bypass (RYGB), Laparoscopic Sleeve Gastrectomy (LSG), MGB/OAGB and Adjustable Gastric Band (AGB). The allocation of the procedure is finalised after mutual agreement between the patient and the surgeon taking in consideration the above factors and patient's choice. The data was retrospectively collected by the surgical team at each institution and sent to the lead of the collaborative group. The follow up is conducted by clinical visits, blood tests and radiology \[ultrasound, computed tomography \] when needed.

The procedures were performed between September 2010 and May 2018. A long gastric pouch of average 15cm was constructed over a 34-36F bougie using laparoscopic staplers. The start point of stapling is at the crow's foot. The omentum was only divided in selected cases such as male patients with a very high Body Mass Index (BMI). After identifying the duodeno-jejunal junction, a BPL ranging from 150-300 cm was measured. The end-side /side-side gastro-jejunostomy was made using a combined hand-sewn /stapled technique. Use of drains and closure of Petersen's space varied between different surgeons. The patients were discharged after 2-3 nights. The follow up was ranged from 6 months to 3 years. In the UK the NHS and private practice are following National Institute of Clinical Excellence \[NICE\] guidelines in management and post operative follow up. Thus there is very strict follow up for two years after the operation. The patients are seen two weeks after the primary surgery at which clinical examination, dietary assessment and baseline post operative blood test is performed. Then the patients are seen one month after that, then 3 monthly period for the initial year, and 6 monthly for the last year. During all these visits, clinical, dietary and routine biochemical assessments were conducted. For patients who developed complications, a different and longer pathway of follow up is adopted until they recover and then, discharged to their general practitioners (GPs). The paper was written to comply with STROCSS guidelines (www.strocssguideline.com).
PURPOSE:To provide the title protective material having the woundcuring effect inherent in chitin as well as infection-preventive and bactericidal effects, consisting of iodine-contg. chitin. CONSTITUTION:The objective protective material consisting of chitin <50% in deacetylation degree containing ca.1-30wt.% of iodine. For iodine incorporation, (1) chitin powder, chitin formed product (e.g. textile, film, sponge) or a wound covering protective material made from chitin (e.g. nonwoven fabric) is treated with an iodine ion-contg. aqueous solution; or (2) a chitin dope is admixed with iodine followed by forming. The present antifungal material can be used as a covering protective material for bed sore with high infective frequency or for dental applications, as a coating material for bactericidal gauzes and medical materials, etc., and also, besides the purpose for medical care, can be used as a disinfectant for kitchens and bathtubs or agricultural/ horticultural disinfectant, and for antifungal sheets, antifungal socks, etc.
AIM: Sleep disorders during pregnancy can impact maternal and neonatal outcomes. The objective of this study is to examine the relationship between sleep quality and maternal and neonatal outcomes during the COVID-19 pandemic.
METHOD: This prospective cohort study was conducted at the Educational-Therapeutic Center of Shohadaye Yaftabad Referral Hospital in Tehran, Iran, from December 2020 to September 2022. A total of 198 eligible participants were randomly assigned to either the sleep disorders group or the no sleep disorders group. Data were collected through demographic questionnaires, the Corona Disease Anxiety Scale (CDAS) questionnaire, the Pittsburgh Sleep Quality Index (PSQI), and the checklist for maternal and neonatal outcomes.
RESULTS: At baseline, the sleep disorders and no sleep disorders groups were similar in terms of age, body mass index (before pregnancy), education level, employment status, gravida, parity, abortion, and history of COVID-19. Within the sleep disorders group, there was a statistically significant, direct linear correlation between sleep disorders and FBS 34-36 weeks (r = 0.33, P < 0.001) as well as Corona Disease Anxiety (CDA) (r = 0.35, P < 0.001). The linear regression results indicated that for every unit increase in sleep disorders, the risk of FBS 34-36 weeks increased by 1.09 times (β = 1.09, P < 0.001). Additionally, sleep disorders increased the risk of CDA by 1.36 times (β = 1.36, P < 0.001). The results showed no statistically significant differences in terms of birth weight, type of delivery (vaginal or cesarean section), gestational age (preterm or full term), length of labor stages (first and second stage), Apgar score at minutes 1 and 5, and NICU admission between the two groups.
CONCLUSION: Based on the results, a certain degree of correlation exists between sleep quality and FBS at 34-36 weeks and CDA. These findings underscore the need for future public health guidelines to formulate detailed strategies to improve sleep quality during the COVID-19 pandemic.
1,155,209. Preparation of polymeric ferrous salts. TEIKOKU HORMONE MFG. CO. Ltd. 8 June, 1966 [8 June, 1965; 17 Nov., 1965; 18 Nov., 1965], No. 7453/69. Divided out of 1,155,208. Heading C3P. Ferrous salts of water-soluble carboxyl groupcontaining polymers are prepared by mixing a water-soluble inorganic ferrous salt with a said water-soluble polymer, or an alkali metal, ammonium or amine salt thereof, in an aqueous reaction medium and, if the pH of the reaction medium is below 6, adding alkali to the solution to bring the pH to at least 6; and recovering the solid ferrous salt of the polymer thus obtained. In a modification, the reaction medium is maintained at a pH below 6 and the polymer solution is contacted with an anion-exchange resin whereupon, after separating the solution from the resin, the ferrous polymer salt is recovered by either evaporating the solution under reduced pressure or adding a water-miscible organic solvent, e.g. alcohol or acetone, to precipitate the polymer salt. The ferrous salt used may be the sulphate, chloride, bromide or nitrate, or ferrous alum or Mohr's salt (ferrous ammonium sulphate). The starting polymer is preferably a homopolymer or copolymer of an ethylenically unsaturated carboxylic acid, e.g. acrylic, methacrylic or maleic acid. Suitable comonomers for the acids include styrene, vinyl acetate, vinyl alkyl (C 1 -C 4 ) ethers, alkyl (C 1 -C 4 ) acrylates and alkyl (C 1 -C 4 ) methacrylates. In some examples, a vinyl methyl ether-or vinyl acetate-maleic anhydride copolymer is used as starting polymer, the anhydride groups thereof being hydrolysed to free acid groups in situ in the aqueous reaction medium; and in one Example (No. XVI) the ferrous salt of such vinyl methyl ether-maleic acid copolymer is blended, while in an aqueous medium, with microcrystalline cellulose.
BACKGROUND: The incidence of inflammatory bowel disease (IBD) is increasing. The prevalence of overweight and obesity is increasing in parallel with IBD and could contribute to IBD development. The aim of this study was to assess the relationship between weight change and the risk for IBD.
METHODS: Data gathered from 55,896 adult participants in the three first population-based Trøndelag Health Studies (HUNT1-3), Norway, performed in 1984-2008 was used. The exposure was change in body mass index between two HUNT studies. The outcome was a new IBD diagnosis recorded during a ten-year follow-up period after the exposure assessment. The risk of IBD by weight change was assessed by Cox regression analyses reporting hazard ratios (HRs) and 95% confidence intervals (CIs), adjusted for sex, age, and smoking status.
RESULTS: There were 334 new cases of ulcerative colitis (UC) and 54 of Crohn's disease (CD). Weight loss decreased the risk of a new UC diagnosis by 38% (adjusted HR 0.62, 95% CI 0.39-0.97) and seemed to double the risk of getting a new CD diagnosis (adjusted HR 2.01, 95% CI 0.91-4.46). Weight gain was not associated with a new diagnosis of neither UC (adjusted HR 1.00, 95% CI 0.78-1.26) nor CD (adjusted HR 1.08, 95% CI 0.56-2.08).
CONCLUSION: In this study, weight loss was associated with decreased risk of UC. However, no associations were seen between weight gain and the risk of UC or CD, suggesting that the increasing weight in the general population cannot explain the increasing incidence of IBD.
The present invention relates to ganoderma and almond oil which comprises 1 to 50 weight parts of dry ganoderma and 50 to 99 weight parts of almond oil. After the ganoderma is dried and pulverized, the fineness reaches more than 700 meshes. The pulverized ganoderma is radiated by Co60-gamma rays in the irradiation absorption dosage of 5 to 8 kGy and uniformly mixed with the almond oil at low temperature below 30 DEG C to obtain the ganoderma and almond oil of the present invention. The ganoderma and the almond oil fully exerts the synergic massage action of the ganoderma and the almond oil by proportioning the ganoderma and the almond oil according to the proportion. The present invention has the advantages of high safety and no side effect, reduces or smoothens fine wrinkles by massaging and wiping, increases the elasticity of the skin. In addition, the ganoderma and almond oil recovers the natural luster of the skin, enhances the resistance to the influence on the skin caused by time, sunlight, pollution and pressure, keeps the young state of the skin, and furthermore, the ganoderma and almond oil has no dependency for long-term use, is suitable for various kinds of skin and is a good health-care and skin-care product.
In this observational single-arm study, a total of 45 patients with metastatic spinal tumors will be enrolled. The patients were aged between 18 and 75 years old. And all the subjects should meet the inclusion criteria and sign the informed consent. Meanwhile, the patients' medical history characteristics, including gender, age, imaging data (X-ray, CT, MRI, or PET-CT, etc.), primary tumor type, pathological type, previous treatment, previous disease history, tumor markers and bone metabolism indexes were collected and recorded on the CRF. The metastatic spinal tumors by stereotactic radiotherapy(SBRT) using TomoTherapy. The adiotherapy dose is 6Gy×5Fx, 5Gy×5Fx or 4Gy×5Fx according to the irradiation site. Treatment should be interrupted if there is severe bone marrow suppression, vertebral compression fracture, or radiation myelitis. The adjacentnormal tissue constrains refer to the UK SABR Consortium Guidelines (2022 version). Follow-up was performed 1 month after radiotherapy, thereafter every 3 months for 1-4 years. The parameters includ blood routine, liver and kidney function, bleeding and coagulation function, bone metabolism index, tumor markers, bone metastasis imaging examination. Tumor response will refer to the Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.
The invention discloses a glycopeptide with immunoregulatory activity and application thereof. The glycopeptides are derived from chicken egg transferrin and include 14N-linked structures. The peptide segment part of the glycopeptide comprises TAGWVIPMGLIHNR and FGVNSCEK, the glycosylation site comprises 492 and 637, and the sugar chain contains N-acetylglucosamine, mannose and galactose. The glycosylation site of the glycopeptide peptide TAGWVIPMGLIHNR is 492, 12N-linked sugar chains, and the glycosylation site of the peptide FGVNGSEK is 637, 2N-linked sugar chains. The glycopeptide with immunoregulation provided by the invention can promote mouse macrophage RAW264.7 to secrete TNF-alpha. Transcriptome sequencing and proteomics and phosphorylation modification group analysis show that differential expressed genes, proteins, phosphorylated proteins of glycopeptides and panel cells are mainly focused on classical immune signaling pathways such as "TNF signaling pathway", "NF-kappa B signaling pathway", etc. The glycopeptide has high biocompatibility, tolerance and strong safety, and can be used as a promising candidate adjuvant.